D'AIUTO E

Last name: D'AIUTO E

2007 (v1)

Publication

Metadata-only

Functional changes in scleroderma fibroblasts co-cultured with autologous peripheral blood mononuclear cells (PBMCS)

VETTORI, Serena DE PALMA, Raffaele Malanga D

No description

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

Morgillo F Cascone T D'Aiuto E

No description

Uploaded on: April 14, 2023
2014 (v1)

Publication

Metadata-only

Local cytokine production in patients with Acute Coronary Syndromes: a look into the eye of the perfect (cytokine) storm

Cirillo P Cimmino G D'Aiuto E

No description

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach

MARTINELLI, Erika TROIANI, Teresa MORGILLO, Floriana

No description

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

Troiani T Martinelli E Napolitano S

PURPOSE: Although cetuximab, an anti-EGF receptor (EGFR) monoclonal antibody, is an effective treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC), its clinical use is limited by onset of resistance. EXPERIMENTAL DESIGN: We characterized two colorectal cancer models to study the mechanisms of acquired resistance to...

Uploaded on: April 14, 2023
2012 (v1)

Publication

Metadata-only

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

Troiani T Vecchione L Martinelli E

Background:MEK is activated in ∼40% colorectal cancer (CRC) and 20-30% non-small cell lung cancer (NSCLC). Selumetinib is a selective inhibitor of MEK1/2, which is currently in clinical development.Methods:We evaluated the effects of selumetinib in vitro and in vivo in CRC and NSCLC cell lines to identify cancer cell characteristics correlating...

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines

MORGILLO, Floriana SASSO, Ferdinando Carlo Della Corte CM

No description

Uploaded on: March 27, 2023

D'AIUTO E

Recent uploads